Literature DB >> 10737472

Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria.

K H Tsui1, O Shvarts, R B Smith, R A Figlin, J B deKernion, A Belldegrun.   

Abstract

PURPOSE: We determine independent prognostic indicators for renal cell carcinoma using the revised 1997 TNM staging criteria.
MATERIALS AND METHODS: The records of 643 consecutive patients undergoing partial or radical nephrectomy at our institution between 1987 and 1998 were reviewed. Preoperative evaluation of functional status using the Eastern Cooperative Oncology Group (ECOG) criteria was performed in all cases. Renal cell carcinoma grade and stage were evaluated using the 1997 American Joint Committee on Cancer grading and TNM staging criteria, respectively. Patients were followed for a mean plus or minus standard deviation of 47+/-40 months (median 87). Kaplan-Meier survival curves were used to determine 5-year cancer specific survival for all patient groups. Univariate analysis using log rank sum tests was performed to evaluate the prognostic significance of overall TNM stage, tumor stage, disease grade and ECOG status. Multivariate analysis was performed to determine which factors had an independent impact on survival of patients with renal cell carcinoma.
RESULTS: The 5-year cancer specific survival rate was 91%, 74%, 67% and 32% for TNM stages I, II, III and IV lesions, respectively (p<0.001). Analysis demonstrated a survival rate of 83% for stage T1, 57% for stage T2, 42% for stage T3 and 28% for stage T4 disease (p<0.001), and 89% for grade 1, 65% for grade 2, and 46% for grades 3 and 4 (p<0.001). Multivariate analysis revealed that overall TNM stage and grade of disease were the most important prognostic indicators for renal cell carcinoma (p<0.001). ECOG classification was a less significant predictor (p = 0.031) and tumor stage was not shown to have any independent impact on patient survival (p = 0.138).
CONCLUSIONS: Better survival rates of patients with localized and advanced renal cell carcinoma can be demonstrated with recent advances in diagnosis and treatment. The revised 1997 TNM criteria manifest an appropriate adjustment in staging renal cell carcinoma based on these improvements, with overall stage correlating with cancer specific survival. In contrast, while effectively predicting survival, tumor stage did not demonstrate an independent impact on renal cell carcinoma prognosis under multivariate analysis. Instead, other factors, such as ECOG status and more importantly grade of disease, appeared to affect survival significantly as independent elements. Based on our recent experience with patients treated for renal cell carcinoma in the era of enhanced technology and improved survival, tumor grade and molecular markers may serve as useful adjuncts to TNM staging in guiding treatment and predicting survival outcomes.

Entities:  

Mesh:

Year:  2000        PMID: 10737472     DOI: 10.1016/s0022-5347(05)67699-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  75 in total

1.  Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification.

Authors:  M Takahashi; D R Rhodes; K A Furge; H Kanayama ; S Kagawa; B B Haab; B T Teh
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

2.  Active surveillance as the preferred management option for small renal masses.

Authors:  Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

3.  [Renal cell carcinoma].

Authors:  A Haferkamp; D Rohde; S C Müller; H Rübben; M Hohenfellner
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 4.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

5.  The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.

Authors:  Dietmar W Siemann; W D Brazelle; Juliane M Jürgensmeier
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-01       Impact factor: 7.038

6.  Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.

Authors:  Daniel J George; Jean-Francois Martini; Michael Staehler; Robert J Motzer; Ahmed Magheli; Frede Donskov; Bernard Escudier; Sherry Li; Michelle Casey; Olga Valota; Brigitte Laguerre; Allan J Pantuck; Hardev S Pandha; Anup Patel; Maria Lechuga; Alain Ravaud
Journal:  Clin Cancer Res       Date:  2018-11-06       Impact factor: 12.531

Review 7.  Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients.

Authors:  Tracy M Downs; Matthew Schultzel; Helen Shi; Catherine Sanders; Zunera Tahir; Georgia Robins Sadler
Journal:  Crit Rev Oncol Hematol       Date:  2008-11-06       Impact factor: 6.312

8.  Staging of renal cell carcinoma: Current concepts.

Authors:  John S Lam; Tobias Klatte; Alberto Breda
Journal:  Indian J Urol       Date:  2009 Oct-Dec

9.  Is there any potential link among caspase-8, p-p38 MAPK and bcl-2 in clear cell renal cell carcinomas? A comparative immunohistochemical analysis with clinical connotations.

Authors:  Vassilis Samaras; Maria Tsopanomichalou; Angeliki Stamatelli; Christos Arnaoutoglou; Efstathios Samaras; Marianthi Arnaoutoglou; Hercules Poulias; Calypso Barbatis
Journal:  Diagn Pathol       Date:  2009-02-17       Impact factor: 2.644

Review 10.  From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma.

Authors:  Androu Arsanious; Georg A Bjarnason; George M Yousef
Journal:  Mol Cancer       Date:  2009-03-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.